Development, optimization, and characterization of polymeric electrospun nanofiber: a new attempt in sublingual delivery of nicorandil for the management of angina pectoris
Source abstract
Abstract
The objective of the current investigation was to develop a novel biocomposite polymeric nanofiber for sublingual delivery of nicorandil in an attempt to reduce mucosal ulceration and to improve drug bioavailability. Polymeric nanofibers were achieved using vitamin B12 and a blend of hyaluronic acid and polyvinyl alcohol as polymeric constituents. The electrospinning method was used to prepare drug (nicorandil)-loaded nanofibers. The resulting nanofibers were characterized for morphology, drug loading, XRD, DSC, in vitro drug release, degree of swelling, and pharmacokinetic behavior. The prepared nanofibers were found to be uniform, non-beaded, and non-woven, with fiber diameter ranging from 200-450 nm. In vitro drug release substantiated the controlled release behavior of the developed formulation. Histopathology studies demonstrated no evidence of mucosal ulceration at the site of application. Pharmacokinetic studies established the preclinical safety and showed the maintenance of an effective therapeutic level for a prolonged period. The present investigation gives inputs showing that the biocomposite nanofiber assists as a perfect carrier system for sublingual delivery of anti-anginal drugs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Nerve injury and regeneration · Conducting polymers and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India
References (75)
Show source-provided references
1. 10.1016/j.ijpharm.2015.02.07010.1016/j.ijpharm.2015.02.070 ↗
2. 10.3109/1061186X.2014.95066410.3109/1061186X.2014.950664 ↗
3. 10.3109/21691401.2014.100049310.3109/21691401.2014.1000493 ↗
4. 10.1038/nature0797010.1038/nature07970 ↗
5. 10.1016/0002-9149(89)90201-410.1016/0002-9149(89)90201-4 ↗
6. Fuster V, Kelly B. 2010. Committee on preventing the global epidemic of cardiovascular disease: meeting the challenges in developing countries; institute of medicine. Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. Washington (DC), US: National Academies Press.
7. 10.1016/j.ejps.2013.11.01610.1016/j.ejps.2013.11.016 ↗
8. 10.3109/21691401.2014.91671510.3109/21691401.2014.916715 ↗
9. Garg T · J Drug Target · 2015 · 1
10. 10.2174/2210304x1120204000510.2174/2210304x11202040005 ↗
11. 10.1517/17425247.2014.89101410.1517/17425247.2014.891014 ↗
12. 10.2174/2210303111303666001510.2174/22103031113036660015 ↗
13. 10.2174/221030310399913121111041410.2174/2210303103999131211110414 ↗
14. 10.2174/2210304x1120204000310.2174/2210304x11202040003 ↗
15. 10.1615/CritRevTherDrugCarrierSyst.201401110410.1615/CritRevTherDrugCarrierSyst.2014011104 ↗
16. Garg T · Curr Drug Deliv · 2015
17. 10.1615/CritRevTherDrugCarrierSyst.201401012210.1615/CritRevTherDrugCarrierSyst.2014010122 ↗
18. Garg T · J Drug Target · 2014 · 1
19. Garg T · Drug Deliv · 2014
20. 10.3109/21691401.2015.100850810.3109/21691401.2015.1008508 ↗
21. Garg T · Int J Pharm Sci Rev Res · 2011 · 7 · 211
22. Garg T · J Pharm Res · 2011 · 4 · 2097
23. 10.1615/CritRevTherDrugCarrierSyst.v29.i1.1010.1615/CritRevTherDrugCarrierSyst.v29.i1.10 ↗
24. 10.1615/CritRevTherDrugCarrierSyst.201300725910.1615/CritRevTherDrugCarrierSyst.2013007259 ↗
25. 10.1007/978-3-662-45775-7_410.1007/978-3-662-45775-7_4 ↗
26. Goyal G · Drug Deliv · 2013
27. 10.1615/CritRevTherDrugCarrierSyst.201400811710.1615/CritRevTherDrugCarrierSyst.2014008117 ↗
28. 10.1615/CritRevTherDrugCarrierSyst.201401012310.1615/CritRevTherDrugCarrierSyst.2014010123 ↗
29. 10.1002/anie.20060464610.1002/anie.200604646 ↗
30. 10.1002/adhm.20130060510.1002/adhm.201300605 ↗
31. 10.1166/jbt.2014.121410.1166/jbt.2014.1214 ↗
32. 10.1007/BF0030510210.1007/BF00305102 ↗
33. 10.3109/10717544.2014.92876010.3109/10717544.2014.928760 ↗
34. 10.3109/10717544.2014.93553110.3109/10717544.2014.935531 ↗
35. Joshi D · Curr Drug Deliv · 2014
36. 10.3109/21691401.2014.98430310.3109/21691401.2014.984303 ↗
37. 10.2174/2210303111303666001810.2174/22103031113036660018 ↗
38. 10.3109/10717544.2015.101965310.3109/10717544.2015.1019653 ↗
39. 10.3109/21691401.2014.98430210.3109/21691401.2014.984302 ↗
40. 10.1615/CritRevTherDrugCarrierSyst.201400828510.1615/CritRevTherDrugCarrierSyst.2014008285 ↗
41. Kaur M · Drug Deliv · 2014
42. 10.3109/10717544.2014.99348610.3109/10717544.2014.993486 ↗
43. 10.3109/21691401.2015.101226010.3109/21691401.2015.1012260 ↗
44. 10.3109/10717544.2014.99348610.3109/10717544.2014.993486 ↗
45. 10.3109/10717544.2014.99348610.3109/10717544.2014.993486 ↗
46. Kaur P · J Drug Target · 2014 · 1
47. 10.3109/21691401.2014.98430210.3109/21691401.2014.984302 ↗
48. 10.3109/10717544.2014.99348610.3109/10717544.2014.993486 ↗
49. 10.1615/CritRevTherDrugCarrierSyst.201401052710.1615/CritRevTherDrugCarrierSyst.2014010527 ↗
50. Kaur V · J Drug Target · 2014 · 1
51. 10.1016/j.ejps.2015.01.01210.1016/j.ejps.2015.01.012 ↗
52. 10.1038/nbt117110.1038/nbt1171 ↗
53. 10.3390/ijms14112164710.3390/ijms141121647 ↗
54. Malik R · J Drug Target · 2014 · 1
55. 10.3109/21691401.2014.100049210.3109/21691401.2014.1000492 ↗
56. 10.3109/10717544.2014.93553210.3109/10717544.2014.935532 ↗
57. Maton A · 1997
58. 10.3109/21691401.2014.92400710.3109/21691401.2014.924007 ↗
59. Modgill V · Curr Drug Deliv · 2014
60. 10.3109/21691401.2014.92787910.3109/21691401.2014.927879 ↗
61. 10.3109/21691401.2014.96619510.3109/21691401.2014.966195 ↗
62. 10.1016/j.biomaterials.2008.04.00210.1016/j.biomaterials.2008.04.002 ↗
63. 10.3109/10717544.2014.94501810.3109/10717544.2014.945018 ↗
64. 10.3109/10717544.2014.94501810.3109/10717544.2014.945018 ↗
65. Sharma A · Artif Cells Nanomed Biotechnol · 2014 · 1
66. 10.3109/21691401.2015.101226110.3109/21691401.2015.1012261 ↗
67. Sharma R · Artif Cells Nanomed Biotechnol · 2014 · 1
68. 10.1615/CritRevTherDrugCarrierSyst.201400819310.1615/CritRevTherDrugCarrierSyst.2014008193 ↗
69. Singh B · Artif Cells Nanomed Biotechnol · 2014 · 1
70. Singh H · Artif Cells Nanomed Biotechnol · 2014
71. Singh K · Am J Pharm Tech Res · 2012 · 2 · 113
72. 10.1155/2014/35242510.1155/2014/352425 ↗
73. 10.1016/j.ijpharm.2014.07.01710.1016/j.ijpharm.2014.07.017 ↗
74. 10.1016/j.ijpharm.2005.01.04210.1016/j.ijpharm.2005.01.042 ↗
75. 10.1021/bm101305210.1021/bm1013052 ↗